RETRACTED: Cancer-associated fibroblasts-derived exosomes upregulate microRNA-135b-5p to promote colorectal cancer cell growth and angiogenesis by inhibiting thioredoxin-interacting protein

Yin, Hua; Yu, Shanshan; Xie, Yangyang; Dai, Xiaoyu; Dong, Mingjun; Sheng, Changrui; Hu, Jingjing

doi:10.1016/j.cellsig.2021.110029

Cited by 54 publications

(51 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several studies provide consistent evidence that TF/thrombin pathway, apart from thrombosis, is involved in the inflammatory and fibrotic processes [ 27 , 54 ]. Mechanistically, fibroblast-derived extracellular vesicles/exosomes or microparticles could transfer active TF to the lung tissue environment [ [55] , [56] , [57] ]. According to recent studies [ 11 , 13 , 31 ], combined targeting against other involved mediators, specifically in early stages, such as complement anaphylatoxins, may further diminish the mortality rate.…”

Section: Discussionmentioning

confidence: 99%

Combined administration of inhaled DNase, baricitinib and tocilizumab as rescue treatment in COVID-19 patients with severe respiratory failure

Gavriilidis

Antoniadou

Chrysanthopoulou

et al. 2022

Clinical Immunology

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Combined administration of inhaled DNase, baricitinib and tocilizumab as rescue treatment in COVID-19 patients with severe respiratory failure

Gavriilidis

Antoniadou

Chrysanthopoulou

et al. 2022

Clinical Immunology

View full text Add to dashboard Cite

“…Several studies provide consistent evidence that TF/thrombin pathway, apart from thrombosis, is involved in inflammation and fibrotic process [27,58]. Mechanistically, fibroblasts-derived extracellular vesicles/exosomes or microparticles could transfer active TF to the lung tissue environment [59–61]. According to recent studies [11,13,32], combined targeting against other involved mediators, specifically in early stages, such as complement anaphylatoxins, may further diminish the mortality rate.…”

Section: Discussionmentioning

confidence: 99%

Combined administration of inhaled DNase, baricitinib and tocilizumab as rescue treatment in COVID-19 patients with severe respiratory failure

Gavriilidis

Antoniadou

Chrysanthopoulou

et al. 2022

Preprint

View full text Add to dashboard Cite

COVID-19-related severe respiratory failure (SRF) leads to mechanical ventilation increasing the in-hospital mortality substantially. Abundancy of lung fibroblasts (LFs) in injured lung tissue has been associated with the progression of respiratory failure in COVID-19. Aiming to reduce mortality in patients with SRF (PaO2/FiO2<100 mmHg) and considering the multi-mechanistic nature of severe COVID-19 pathogenesis, we applied a combined rescue treatment (COMBI) on top of standard-of-care (SOC: dexamethasone and heparin) comprised inhaled DNase to dissolve thrombogenic neutrophil extracellular traps, plus agents against cytokine-mediated hyperinflammation, such as anti-IL-6 receptor tocilizumab and selective JAK1/2 inhibitor baricitinib. COMBI (n=22) was compared with SOC (n= 26), and with two previously and consecutively used therapeutic approaches, including either IL-1 receptor antagonist anakinra (ANA, n=19), or tocilizumab (TOCI, n=11), on top of SOC. In parallel, evaluation of immunothrombosis was assessed in vitro in human LFs, treated with the applied therapeutic agents upon stimulation with COVID-19 plasma. COMBI was associated with lower in-hospital mortality (p=0.014) and intubation rate (p=0.013), shorter duration of hospitalization (p=0.019), and prolonged overall survival after a median follow-up of 110+/-4 days (p=0.003). In vitro, COVID-19 plasma markedly induced tissue factor/thrombin pathway in LFs, while this effect was inhibited by the immunomodulatory agents of COMBI providing a mechanistic explanation for the clinical observations. These results suggest the design of randomized trials using combined immunomodulatory therapies in COVID-19-associated SRF targeting multiple interconnected pathways of immunothrombosis.

show abstract

“…Yin et al. ( 93 ) have revealed that exosomes upregulating miR-135b-5p promoted in vivo growth, in vitro proliferation, migration, and invasion, and suppressed the apoptosis of colorectal cancer (CRC) cells. As a key component, exosomal proteins also perform vital functions in tumorigenesis.…”

Section: Exosomesmentioning

confidence: 99%

Emerging Role of Cancer-Associated Fibroblasts-Derived Exosomes in Tumorigenesis

et al. 2022

View full text Add to dashboard Cite

Cancer-associated fibroblasts (CAFs) are the most important component of the stromal cell population in the tumor microenvironment and play an irreplaceable role in oncogenesis and cancer progression. Exosomes, a class of small extracellular vesicles, can transfer biological information (e.g., proteins, nucleic acids, and metabolites as messengers) from secreting cells to target recipient cells, thereby affecting the progression of human diseases, including cancers. Recent studies revealed that CAF-derived exosomes play a crucial part in tumorigenesis, tumor cell proliferation, metastasis, drug resistance, and the immune response. Moreover, aberrant expression of CAF-derived exosomal noncoding RNAs and proteins strongly correlates with clinical pathological characterizations of cancer patients. Gaining deeper insight into the participation of CAF-derived exosomes in tumorigenesis may lead to novel diagnostic biomarkers and therapeutic targets in human cancers.

show abstract

RETRACTED: Cancer-associated fibroblasts-derived exosomes upregulate microRNA-135b-5p to promote colorectal cancer cell growth and angiogenesis by inhibiting thioredoxin-interacting protein

Cited by 54 publications

References 40 publications

Combined administration of inhaled DNase, baricitinib and tocilizumab as rescue treatment in COVID-19 patients with severe respiratory failure

Combined administration of inhaled DNase, baricitinib and tocilizumab as rescue treatment in COVID-19 patients with severe respiratory failure

Combined administration of inhaled DNase, baricitinib and tocilizumab as rescue treatment in COVID-19 patients with severe respiratory failure

Emerging Role of Cancer-Associated Fibroblasts-Derived Exosomes in Tumorigenesis

Contact Info

Product

Resources

About